CLLS | Cellectis SA 18.78 -0.18 (-0.95%)
Category: Company
Quick infos Trade prices Volume: Market Cap: 818.81M Prev closed: 18.65 Open: 18.85 High: 19.27 Low: 18.66 52 week low: 7.32 52 week high: 21.97 Dividends: No Dividends Next ER: May 5, 2021
About the Company Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris and New York City.
Earnings History Date EPS / Forecast Revenue / Forecast May 12, 2021 March 4, 2021 -0.33 / -0.781113.9M / 7.25MBeat! November 5, 2020 -0.71 / -0.61339.24M / 10.36MAugust 5, 2020 -0.76 / -0.742.9M / 4.58MBeat! May 6, 2020 0.47 / -0.6451.91M / 16.23MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Mar 31, 2021 20.31 18.58 20.60
18.58
208.12K 7.97% Mar 30, 2021 18.81 18.55 19.35
18.40
220.61K -1.52% Mar 29, 2021 19.10 19.05 19.30
18.50
161.49K -0.21% Mar 26, 2021 19.14 19.51 19.59
18.17
190.99K -2.05% Mar 25, 2021 19.54 18.51 19.83
17.81
466.53K 5.62% Mar 24, 2021 18.50 20.27 20.27
18.31
479.52K -8.91% Mar 23, 2021 20.31 21.24 21.32
20.03
193.99K -6.28% Mar 22, 2021 21.67 21.38 22.20
21.00
219.11K 1.12% Mar 19, 2021 21.43 20.02 21.43
20.02
378.06K 8.18% Mar 18, 2021 19.81 20.71 21.12
19.75
205.92K -6.69% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:1999 Employees:122 News
Cellectis SA (CLLS) Q3 2020 Earnings Call Transcript fool.com Mar 16, 2021 2:00 pm
Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications finance.yahoo.com Mar 16, 2021 8:55 am
Monthly information on share capital and company voting rights finance.yahoo.com Mar 12, 2021 4:30 pm
Cellectis: Q4 Earnings Insights finance.yahoo.com Mar 4, 2021 5:22 pm
Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST finance.yahoo.com Feb 25, 2021 4:30 pm
Cellectis: Monthly information on share capital and company voting rights finance.yahoo.com Feb 10, 2021 4:30 pm
Monthly information on share capital and company voting rights finance.yahoo.com Jan 6, 2021 4:30 pm
Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics, UniQure, Celgene, Cellectis and Sangamo Therapeutics - PRNewswire prnewswire.com Dec 19, 2020 1:12 am
Cellectis (CLLS) Jumps: Stock Rises 9% - Yahoo Finance finance.yahoo.com Dec 17, 2020 2:12 pm
Cellectis Announces Withdrawal of Follow-On Offering Paris Stock Exchange:ALCLS - GlobeNewswire globenewswire.com Dec 16, 2020 10:12 pm
Cellectis Announces Withdrawal of Follow-On Offering - Yahoo Finance finance.yahoo.com Dec 16, 2020 12:12 pm
Thinking about buying stock in Aphria, Drive Shack, Gevo, Cellectis, or Sesen Bio? - PRNewswire prnewswire.com Dec 16, 2020 12:12 pm Cellectis withdraws follow-on offering - Seeking Alpha seekingalpha.com Dec 16, 2020 7:12 am
BUZZ-U.S. STOCKS ON THE MOVE-Diana Shipping, Cellectis, Moderna - Nasdaq nasdaq.com Dec 15, 2020 1:12 pm This company doesn't provide a dividend.
Key Persons CEO : André Choulika, PhD Talk about Cellectis SA below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 100 HOLD 0 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.